Arsenic trioxide medac Europese Unie - Roemeens - EMA (European Medicines Agency)

arsenic trioxide medac

medac gesellschaft für klinische spezialpräparate mbh - trioxid de arsen - leucemie, promielocitară, acută - agenți antineoplazici - arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 10³/μl) in combination with all-trans-retinoic acid (atra)relapsed/refractory apl (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rarα) gene. rata de răspuns de alte leucemie mieloidă acută subtipuri de trioxid de arsen nu a fost examinată.